[1]
|
金栋材, 赵丽. 复发/难治性霍奇金淋巴瘤治疗策略的研究进展[J]. 中国实验血液学杂志, 2020, 28(1): 343-349.
|
[2]
|
Ansell, S.M. (2018) Hodgkin Lymphoma: 2018 Update on Diagnosis, Risk-Stratification, and Manage-ment. American Journal of Hematology, 93, 704-715. https://doi.org/10.1002/ajh.25071
|
[3]
|
Timothy, J.V. and Beaven, A.W. (2020) Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers, 12, 2887. https://doi.org/10.3390/cancers12102887
|
[4]
|
Hamadani, M., Balasubramanian, S. and Hari, P.N. (2015) Ibrutinibin Refractory Classic Hodgkin’s Lymphoma. The New England Journal of Medicine, 373, 1381-1382. https://doi.org/10.1056/NEJMc1505857
|
[5]
|
Du, J., Neuenschwander, M., Yu. Y., et al. (2017) Pharmacological Restoration and Therapeutic Targeting of the B-Cell Phenotype in Classical Hodgkin Lymphoma. Blood, 129, 71-81. https://doi.org/10.1182/blood-2016-02-700773
|
[6]
|
王金妮, 刘爱春. 晚期经典型霍奇金淋巴瘤的治疗进展[J]. 现代肿瘤医学, 2021, 29(4): 688-692.
|
[7]
|
中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会和中国霍奇金淋巴瘤工作组. 中国霍奇金淋巴瘤的诊断与治疗指南(2022年版) [J]. 中华血液学杂志, 2022, 43(9): 705-715.
|
[8]
|
Ullah, F., Dima, D., Omar, N., et al. (2023) Advances in the Treatment of Hodgkin Lymphoma: Current and Future Approaches. Frontiers in Oncology, 13, Article ID: 1067289. https://doi.org/10.3389/fonc.2023.1067289
|
[9]
|
Dong, R., Yan, Y., Zeng, X., et al. (2022) Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Design, Development and Therapy, 16, 3225-3239. https://doi.org/10.2147/DDDT.S377697
|
[10]
|
Alu, A., Lei, H., Han, X., et al. (2022) BTK Inhibitors in the Treat-ment of Hematological Malignancies and Inflammatory Diseases: Mechanisms and Clinical Studies. Journal of Hema-tology & Oncology, 15, Article No. 138.
https://doi.org/10.1186/s13045-022-01353-w
|
[11]
|
Balaji, S., Ahmed, M., Lorence, E., et al. (2018) NF-κB Signal-ing and Its Relevance to the Treatment of Mantle Cell Lymphoma. Journal of Hematology & Oncology, 11, Article No. 83. https://doi.org/10.1186/s13045-018-0621-5
|
[12]
|
Pan, Z., Scheerens, H., Li, S.-J., et al. (2007) Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem, 2, 58-61. https://doi.org/10.1002/cmdc.200600221
|
[13]
|
Fernández-Vega, I., Quirós, L.M., Santos-Juanes, J., Pane-Foix, M. and Marafioti, T. (2015) Bruton’s Tyrosine Kinase (Btk) Is a Useful Marker for Hodgkin and B Cell Non-Hodgkin Lymphoma. Virchows Archiv: An International Journal of Pathology, 466, 229-235. https://doi.org/10.1007/s00428-014-1698-z
|
[14]
|
Brown, J.R. (2013) Ibrutinib (PCI-32765), the First BTK (Bru-ton’s Tyrosine Kinase) Inhibitor in Clinical Trials. Current Hematologic Malignancy Reports, 8, 1-6. https://doi.org/10.1007/s11899-012-0147-9
|
[15]
|
Ran, F., Liu, Y., Wang, C., et al. (2022) Review of the Develop-ment of BTK Inhibitors in Overcoming the Clinical Limitations of Ibrutinib. European Journal of Medicinal Chemistry, 229, Article ID: 114009.
https://doi.org/10.1016/j.ejmech.2021.114009
|
[16]
|
Badar, T., Astle, J., Kakar, I.K., et al. (2020) Clinical Activity of Ibrutinib in Classical Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation Is Independent of Tumor BTK Expression. British Journal of Haematology, 190, e98-e101. https://doi.org/10.1111/bjh.16738
|
[17]
|
Szklener, K., Michalski, A., Żak, K., et al. (2022) Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Fu-ture Directions. Cells, 11, 1338. https://doi.org/10.3390/cells11081338
|
[18]
|
张燕芳, 朱晨影, 康媛源, 等. 砷剂联合方案抗血液肿瘤的临床应用与研究进展[J]. 中国现代应用药学, 2023, 49(9): 1260-1269.
|
[19]
|
Huang, Q., Wang, T., Xiong, Y., et al. (2022) Safety and Efficacy of Compound Huangdai Tablets Combined with All-Trans Retin-oic Acid for Treatment of Acute Promyelocytic Leukemia: Clinical Evidence and Potential Mechanisms. Chinese Herbal Medicines, 14, 154-165. https://doi.org/10.1016/j.chmed.2021.09.004
|